Spots Global Cancer Trial Database for An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Official Title: An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Study ID: NCT01240421
Conditions
Interventions
Study Description
Brief Summary: This expanded access program is an open-label, multi-center study, which will consist of a PreTreatment Phase and a Treatment Phase. Patients with locally advanced or metastatic breast cancer who fulfill the eligibility criteria will be treated. The program will continue in each country until eribulin is approved, reimbursed and launched in that country, or termination of the program by the Sponsor.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
, Brussels, , Belgium
, Edmonton, , Canada
, London, , Canada
, Moncton, , Canada
, Montreal, , Canada
, Ottawa, , Canada
, Quebec, , Canada
, Toronto, , Canada
, Vancouver, , Canada
, Besancon, , France
, Marseille Cedex 09, , France
, Paris Cedex 05, , France
, Saint-cloud, , France
, Toulouse cedex, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
